Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea (ERASE)
A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers
Sponsor: Dr. Falk Pharma GmbH
This PHASE3 trial investigates Traveler's Diarrhea and is currently completed. Dr. Falk Pharma GmbH leads this study, which shows 10 recorded versions since 2010 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dr. Falk Pharma GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ajmer, India , Bardez, India , Calangute, India , Hyderabad, India , Kolkata, India , Lucknow, India , Madgaon, India , Mapusa, India , New Delhi, India , Panjim, India and 8 more locations